VGX Pharmaceuticals (Formerly Known as Viral Genomix, Inc.)’ Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models

MALAGA, Spain--(BUSINESS WIRE)--VGX Pharmaceuticals’ novel pandemic influenza vaccine candidates triggered protective immune responses in pre-clinical challenge studies, according to data presented for the first time today at the Third International Conference on DNA Vaccines in Malaga, Spain.